KRAS and NRAS mutational analysis in plasma ctDNA from patients with metastatic colorectal cancer by real-time PCR and digital PCR.
Manuela PinheiroAna PeixotoPatricia RochaIsabel VeigaCarla PintoCatarina SantosPedro PintoJoana GuerraCarla EscudeiroAna BarbosaJoão SilvaManuel R TeixeiraPublished in: International journal of colorectal disease (2022)
Analysis of ctDNA is a viable strategy for clinical management of mCRC patients. Although the OncoBEAM assay sensitivity is somewhat higher, the fully automated Idylla platform also has good performance, while being cheaper and much less labor-intensive, for the detection of RAS mutations in plasma, either at diagnosis or after progression when considering anti-EGFR treatment rechallenge.
Keyphrases
- real time pcr
- high throughput
- metastatic colorectal cancer
- end stage renal disease
- wild type
- ejection fraction
- small cell lung cancer
- newly diagnosed
- chronic kidney disease
- circulating tumor
- prognostic factors
- peritoneal dialysis
- epidermal growth factor receptor
- patient reported outcomes
- combination therapy
- quantum dots
- circulating tumor cells